AVALON GLOBOCARE CORP

Company Overview

Avalon GloboCare Corp (ticker ALBT) is classified in the Real Estate sector and Real Estate Services industry but, following its 2024–2025 restructuring, operates as a small commercial-stage precision-diagnostics and consumer device company. The firm has exited its laboratory services business (Lab Services MSO interest redeemed Feb 26, 2025) and is now focused on commercialization of KetoAir, an FDA-registered Class I handheld breathalyzer that measures exhaled acetone and pairs with an “AI Nutritionist” mobile app. Avalon is highly capital-constrained, with modest recurring rental cash flows from owned real property, suspended R&D to conserve cash, heavy reliance on third-party manufacturing and an exclusive distribution agreement with Qi Diagnostics; management is pursuing additional financing and a potential 2025 merger with YOOV.

Executive Compensation Practices

Compensation at Avalon is likely heavily influenced by near-term commercialization milestones (KetoAir sales, app regulatory status, DTC customer acquisition metrics) and by the company’s constrained liquidity; management already reduced total compensation year‑over‑year (compensation down ~$0.34M in 2024) as part of cost-cutting. Given the small headcount and cash preservation strategy, executives are likely paid lower cash salaries and rely more on equity, options, warrants, convertible preferred rights and performance-based awards tied to financing/transaction outcomes, product launches, or milestone payments from the Qi distributorship. Material financing instruments (secured convertible notes, Series C preferred conversion rights) and investor governance provisions further align executive pay with capital-raising and transaction success, but also increase dilution risk for shareholders and can complicate pay disclosure (valuation of warrants/convertible features affects reported compensation expense). Finally, rental income stability provides a modest non-operational cash cushion that may be factored into compensation benchmarking for the CEO/management given the company’s atypical mix of device commercialization and property ownership.

Insider Trading Considerations

Insider trading patterns at Avalon should be interpreted in light of very limited liquidity, frequent financings, and sizeable conversion- and warrant-related dilution events; insiders selling shares near financing closes, conversion-price adjustments, or public announcements about the YOOV merger or KetoAir launches can signal personal liquidity needs rather than confidence in fundamentals. Material nonpublic information that would create trading blackouts includes product regulatory milestones (app/iOS approvals), the timing and terms of the Qi distribution/manufacturing arrangements, redemption/asset-sale proceeds (Lab Services MSO redemption), and merger negotiations—trades by insiders immediately before or after such events merit scrutiny. Because compensation and incentives are often equity-heavy, expect option exercises, insider sales to cover tax or exercise costs, and transactions tied to convertible-feature adjustments; researchers should watch 10b5‑1 plans, Section 16 filings for clustered transactions, and pre-clearance or controlled‑period disclosures given the company’s small-issuer status and heightened dilution risk. Regulatory considerations (FDA, HIPAA, state privacy laws and anti-fraud statutes) also create circumstances where material nonpublic regulatory developments could drive abrupt insider trading activity and trigger mandatory blackout periods.